EA201070015A1 - Композиции, содержащие антитело - Google Patents

Композиции, содержащие антитело

Info

Publication number
EA201070015A1
EA201070015A1 EA201070015A EA201070015A EA201070015A1 EA 201070015 A1 EA201070015 A1 EA 201070015A1 EA 201070015 A EA201070015 A EA 201070015A EA 201070015 A EA201070015 A EA 201070015A EA 201070015 A1 EA201070015 A1 EA 201070015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions containing
containing antibody
antibody
vla
binding antibody
Prior art date
Application number
EA201070015A
Other languages
English (en)
Other versions
EA020456B1 (ru
Inventor
Кевин Мэлоуни
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of EA201070015A1 publication Critical patent/EA201070015A1/ru
Publication of EA020456B1 publication Critical patent/EA020456B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Описаны композиции, содержащие VLA-4-связывающее антитело.
EA201070015A 2007-06-14 2008-06-13 Фармацевтическая композиция, содержащая связывающееся с vla-4 антитело, для подкожной или внутримышечной доставки EA020456B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14
PCT/US2008/066928 WO2008157356A2 (en) 2007-06-14 2008-06-13 Antibody formulations

Publications (2)

Publication Number Publication Date
EA201070015A1 true EA201070015A1 (ru) 2010-06-30
EA020456B1 EA020456B1 (ru) 2014-11-28

Family

ID=39956053

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070015A EA020456B1 (ru) 2007-06-14 2008-06-13 Фармацевтическая композиция, содержащая связывающееся с vla-4 антитело, для подкожной или внутримышечной доставки

Country Status (24)

Country Link
US (3) US20080311119A1 (ru)
EP (2) EP2170390B1 (ru)
JP (2) JP2010529999A (ru)
CN (2) CN103977404A (ru)
AR (2) AR067011A1 (ru)
AU (1) AU2008266051B2 (ru)
BR (1) BRPI0814252B8 (ru)
CA (1) CA2690382A1 (ru)
CY (1) CY1121208T1 (ru)
DK (1) DK2170390T3 (ru)
EA (1) EA020456B1 (ru)
ES (1) ES2707815T3 (ru)
HR (1) HRP20182146T1 (ru)
HU (1) HUE041555T2 (ru)
IL (1) IL202648B (ru)
LT (1) LT2170390T (ru)
MX (2) MX2009013593A (ru)
NZ (2) NZ582436A (ru)
PL (1) PL2170390T3 (ru)
PT (1) PT2170390T (ru)
SI (1) SI2170390T1 (ru)
TR (1) TR201820837T4 (ru)
TW (1) TWI614028B (ru)
WO (1) WO2008157356A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071439A2 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
NZ602115A (en) 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PT3202789T (pt) 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
WO2013059406A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
BR112014031841A2 (pt) * 2012-06-21 2017-06-27 Ucb Pharma Sa formulação farmacêutica
EP2869817A4 (en) 2012-07-09 2016-04-06 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
BR112015005161A2 (pt) 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
MX2016006571A (es) * 2013-11-29 2016-08-05 Genentech Inc Aparatos y metodos de seleccion de anticuerpo.
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
KR20170052526A (ko) * 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR20170040132A (ko) * 2014-06-02 2017-04-12 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 Fc 단편의 제조
RU2017111228A (ru) * 2014-10-18 2018-11-21 Пфайзер Инк. Композиции антитела против IL-7R
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
AU2020310196A1 (en) * 2019-07-10 2022-01-27 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising reduced level of host cell proteins
CN116472061A (zh) * 2020-10-30 2023-07-21 卫材R&D管理有限公司 药物组合物
AU2021378813A1 (en) 2020-11-14 2023-06-22 Biogen Ma Inc. Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
CA3215371A1 (en) 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994015587A2 (en) 1993-01-06 1994-07-21 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
SG44845A1 (en) * 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2270425T3 (es) * 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
SI9720020B (en) * 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0107862A (pt) 2000-01-27 2002-11-05 American Cyanamid Co Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2004071439A2 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
WO2008021954A2 (en) 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug

Also Published As

Publication number Publication date
CN101778640A (zh) 2010-07-14
US20130017193A1 (en) 2013-01-17
TWI614028B (zh) 2018-02-11
PT2170390T (pt) 2019-02-12
CN103977404A (zh) 2014-08-13
BRPI0814252B8 (pt) 2021-05-25
ES2707815T3 (es) 2019-04-05
JP2014040424A (ja) 2014-03-06
EA020456B1 (ru) 2014-11-28
EP2170390B1 (en) 2018-11-07
MX2020005214A (es) 2020-08-20
EP3461500A1 (en) 2019-04-03
US20080311119A1 (en) 2008-12-18
SI2170390T1 (sl) 2019-02-28
US20120134989A1 (en) 2012-05-31
WO2008157356A2 (en) 2008-12-24
NZ595526A (en) 2013-03-28
AR117403A2 (es) 2021-08-04
BRPI0814252A8 (pt) 2019-01-29
TR201820837T4 (tr) 2019-01-21
CA2690382A1 (en) 2008-12-24
HUE041555T2 (hu) 2019-05-28
HRP20182146T1 (hr) 2019-02-08
BRPI0814252B1 (pt) 2019-12-10
LT2170390T (lt) 2019-01-10
IL202648B (en) 2018-04-30
NZ582436A (en) 2012-06-29
AU2008266051B2 (en) 2014-07-31
WO2008157356A3 (en) 2009-02-19
TW200908995A (en) 2009-03-01
AR067011A1 (es) 2009-09-30
PL2170390T3 (pl) 2019-05-31
JP2010529999A (ja) 2010-09-02
BRPI0814252A2 (pt) 2015-04-14
DK2170390T3 (en) 2019-01-21
US9533044B2 (en) 2017-01-03
EP2170390A2 (en) 2010-04-07
CY1121208T1 (el) 2020-05-29
AU2008266051A1 (en) 2008-12-24
MX2009013593A (es) 2010-01-20
IL202648A0 (en) 2011-08-01
AU2008266051A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
EA201070015A1 (ru) Композиции, содержащие антитело
UA107791C2 (en) Pesticidal compositions
TN2010000213A1 (en) Wise binding antibodies and epitopes
CL2007002182S1 (es) Terminal.
DK3275965T3 (da) Sammensætninger, der omfatter en fluorolefin
MEP35408A (en) Tweak binding antibodies
EA200801959A1 (ru) Высокоразветвленный полипропилен
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
NO20082413L (no) Mikrobiocidal sammensetning
EA201100869A1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и циклофосфамид
ATE493122T1 (de) Casein-komplexe
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
GB2461659A (en) Structured compositions comprising a clay
UY31688A1 (es) Plaguicidas
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
DK2134788T3 (da) Polythioetheraminharpikser og sammensætninger omfattende samme
IT1393413B1 (it) Composizione pesticida.
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
ECSP10010491A (es) Composiciones fungicidas con 3'-bromo-2,3,4,6'-tetrametoxi-2',6-dimetilbenzofenona
FR2923834B1 (fr) Nouvelles compositions polysicocyanates hydrodispersibles.
FR2923713B1 (fr) Composition reductrice epaissie.
FR2928835B1 (fr) Composition depigmentante a base de crocus sativus.
FR2902783B1 (fr) Compositions pyrotechniques thermo-initiables, utilisation.
IT1393582B1 (it) Composizione pesticida.

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent